David Gaiero
Financieel Directeur/CFO bij CYTEIR THERAPEUTICS, INC.
Vermogen: 308 197 $ op 31-03-2024
Profiel
David Gaiero is currently the Chief Financial Officer & Treasurer at Cyteir Therapeutics, Inc. He previously worked as the Chief Financial & Accounting Officer at Wave Life Sciences Ltd.
from 2017 to 2020 and as the Vice President & Global Controller at OvaScience, Inc. from 2015 to 2017.
Mr. Gaiero completed his undergraduate degree at the University of Massachusetts.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 04-03-2024 | 102 391 ( 0.28% ) | 308 197 $ | 31-03-2024 |
Actieve functies van David Gaiero
| Bedrijven | Functie | Begin |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-12-2020 |
Eerdere bekende functies van David Gaiero
| Bedrijven | Functie | Einde |
|---|---|---|
| WAVE LIFE SCIENCES LTD. | Financieel Directeur/CFO | 04-12-2020 |
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Comptroller/Controller/Auditor | 01-01-2017 |
Opleiding van David Gaiero
| University of Massachusetts | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| WAVE LIFE SCIENCES LTD. | Health Technology |
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
